Comments on a meta-analysis and systematic review of the clinicopathological significance of CDH1 in gastric cancer

Chao Tu
Lianwen Yuan
Jianping Zhou

Department of Geriatric Surgery, The Second Xiangya Hospital of Central South University, Changsha, People's Republic of China

Dear editor

With great interest, we read an article entitled “The clinicopathological significance of CDH1 in gastric cancer: a meta-analysis and systematic review” by Zeng et al,¹ which was published in *Drug Design, Development and Therapy* in April 2015. In this meta-analysis, the investigators systematically reviewed the studies on correlation between CDH1 hypermethylation and gastric cancer (GC), and concluded that CDH1 hypermethylation levels in GC and adjacent gastric mucosa are both significantly higher when compared with normal gastric mucosa. Meanwhile, CDH1 hypermethylation is found markedly correlated with *Helicobacter pylori* status. Taken together, CDH1 hypermethylation is positively associated with overall GC risk and the *H. pylori*-positive GC risk.¹ It is a valuable study. Nevertheless, there are several queries that we would like to communicate with the authors.

Only three electronic databases (PubMed, Embase, Web of Science) were systematically searched for eligible studies.¹ The small number of acquired trials could be regarded as a flaw of this meta-analysis. From our perspective, any effort to minimize the bias should be valued; therefore, other common databases including the Cochrane Library, Cochrane Central Register of Controlled Trials, Scopus, CINAHL, CNKI, and CBM disc should be systematically searched as well.

With respect to the data extraction and quality assessment of the included studies, the investigators clarified that two researchers independently collected the information and summarized the data in Table 1,¹ while actually most of the extracted data, including year, sexual status, smoking history, pathological types, clinical staging, differentiation degree, lymph node metastasis, EGFR status, and prognostic conditions, were not displayed in that table. We are wondering why these data were absent. Furthermore, the authors claimed that they appraised the methodological quality of each trial according to REMARK guidelines^{1,2} and the European Lung Cancer Working Party quality scale.³ However, the detailed scores for these selected studies were also not presented in this meta-analysis.

The authors described that heterogeneity between GC tissues and adjacent gastric mucosa/normal mucosa tissues was significant ($P > 50\%$). To make this meta-analysis more credible, subgroup meta-analysis should be performed to further explore the sources of heterogeneity. Moreover, the investigators clarified that “publication bias was detected by the Begg’s test” in the “Methods” section. However, the results of

Correspondence: Jianping Zhou
Department of Geriatric Surgery, The Second Xiangya Hospital of Central South University, No 139, Peoples’ Middle Road, Changsha 410011, Hunan, People’s Republic of China
Tel/fax +86 731 8529 5167
Email xyeyzjp@126.com

Begg's test were not shown in this systematic review. In our opinion, the authors should provide us all the statistical results of publication bias tests to increase its legibility and credibility.

There are some obvious mistakes in this meta-analysis. Firstly, the authors demonstrated that "a systematic literature search was performed using Pubmed, Embase, and Web of Science without any language restriction" in the "Methods" section. However, the authors clarified that "the search strategy was restricted to articles published in English" in the "Discussion" section. Besides, they also claimed that only "Pubmed and Embase databases were searched" for literature retrieval in the "Abstract" section.¹ We are confused by these inconsistent statements and are eager to know the possible reason for these discrepancies. Secondly, there is an obvious typographic error in Figure 1,¹ in which the "Records excluded (n=24)" should be replaced by "Records excluded (n=34)". Thirdly, it is appropriate to adopt random-effects model to calculate the pooled odds ratio in Figure 4, since the heterogeneity between adjacent gastric mucosa and normal gastric mucosa tissues is not significant ($I^2=0$).¹ As far as we know, it would be much better to use fixed-effects model in this circumstance.

We compliment the investigators for their contribution in supplying us with an assessment on the clinicopathological significance of CDH1 in GC. However, these results should be interpreted with caution, since there are several methodological deficiencies in this meta-analysis. In addition, prospective studies with larger sample sizes are still needed to further confirm these findings.

Disclosure

The authors declare no conflicts of interest in this communication.

References

1. Zeng W, Zhu J, Shan L, et al. The clinicopathological significance of CDH1 in gastric cancer: a meta-analysis and systematic review. *Drug Des Devel Ther*. 2015;9:2149–2157.
2. Altman DG, McShane LM, Sauerbrei W, et al. Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration. *BMC Med*. 2012;10:51.
3. Sculier JP, Ghisdal L, Berghmans T, et al. The role of mitomycin in the treatment of non-small cell lung cancer: a systematic review with meta-analysis of the literature. *Br J Cancer*. 2001;84:1150–1155.

Dove Medical Press encourages responsible, free and frank academic debate. The content of the Drug Design, Development and Therapy 'letters to the editor' section does not necessarily represent the views of Dove Medical Press, its officers, agents, employees, related entities or the Drug Design, Development and Therapy editors. While all reasonable steps have been taken to confirm the content of each letter, Dove Medical Press accepts no liability in respect of the content of any letter, nor is it responsible for the content and accuracy of any letter to the editor.

Drug Design, Development and Therapy

Publish your work in this journal

Drug Design, Development and Therapy is an international, peer-reviewed open-access journal that spans the spectrum of drug design and development through to clinical applications. Clinical outcomes, patient safety, and programs for the development and effective, safe, and sustained use of medicines are a feature of the journal, which

Submit your manuscript here: <http://www.dovepress.com/drug-design-development-and-therapy-journal>

has also been accepted for indexing on PubMed Central. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Dovepress